Hepion Pharmaceuticals, Inc. (HEPA) Stock

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to advancing drug therapies for chronic liver diseases across the United States.

Central to its mission is the development of Rencofilstat, a cyclophilin inhibitor that has successfully completed Phase 2a clinical trials. This innovative treatment targets multiple pathological pathways associated with liver disease progression and is currently in clinical phases for addressing non-alcoholic steatohepatitis (NASH). Additionally, Rencofilstat is undergoing nonclinical studies aimed at reducing liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Importantly, the drug has demonstrated promising antiviral effects against hepatitis B, C, and D viruses through various mechanisms.

Originally founded as ContraVir Pharmaceuticals, Inc., the company rebranded to Hepion Pharmaceuticals, Inc. in July 2019. Established in 2013 and headquartered in Edison, New Jersey, Hepion Pharmaceuticals continues to spearhead advancements in therapeutic approaches for chronic liver diseases, underscoring its commitment to improving patient outcomes through innovative research and development efforts.